ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
6153
-
Likes:
7
-
Views:
6153
-
Likes:
7
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial -
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI -
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study -
5m 41s -
3m 46s -
5m 53s -
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients -
5m 21sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF -
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure -
5m 44s -
8m 2s
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up -
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s -
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos -
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays -
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers -
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque -
5m 29s -
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers -
3m 33s -
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023 -
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16m 24sPart 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
-
14m 3sPart 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US) and Dr Christopher B Granger (Duke University Medical Center, US) to discuss the results of the COORDINATE-Diabetes trial.
The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD).
The trial involves cardiology clinics in the US and provides a multi-disciplinary approach to care, including education for clinicians and patients, patient tracking, and monthly clinician calls to review cases. The primary outcome is the proportion of patients receiving all three types of recommended medication (high-intensity statin, ACEi/ARB, and SGLT2i or GLP1RA) at the last follow-up visit.
The trial showed that a coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with T2DM and ASCVD.
Recorded remotely from Hamilton and Durham, 2023.
Faculty Biographies
Christopher B Granger
Associate Professor of Medicine in the Division of Cardiology
Christopher B Granger, MD, is an Associate Professor of Medicine in the Division of Cardiology at Duke University. He is Director of the Cardiac Care Unit and Co-director of Cardiovascular Clinical Trials at the Duke Clinical Research Institute. He is a Fellow of the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), Associate Editor of the American Heart Journal, and serves on the editorial boards of the Journal of the American College of Cardiology and the European Heart Journal. Dr Granger’s primary research interest is in the conduct and methodology of large randomized clinical trials in heart disease. He has co-authored over 200 peer-reviewed manuscripts.
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Neha Pagidipati
Assistant Professor of Medicine
Neha J Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management. She is currently an NIH K12 scholar in Implementation and Dissemination Science.
Dr Pagidipati is building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity.
Dr Pagidipati’s research grants include the COORDINATE-Diabetes Trial, to improve the quality of care for patients with diabetes and cardiovascular disease across the US, and QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data.
In addition, she is leading a large study within the Duke Health System to study heterogeneity within cardiovascular disease risk and…
Comments